West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Ulrike A NitzWest German Study Group PlanB Investigators

Abstract

The West German Study Group PlanB trial evaluated an anthracycline-free chemotherapy standard (six cycles of docetaxel and cyclophosphamide [TC]) in the routine treatment of human epidermal growth factor receptor 2-negative early breast cancer (EBC). Patients with pT1 to pT4c, all pN+, and pN0/high-risk EBC were eligible. High-risk pN0 was defined by one or more of the following: pT greater than 2, grade 2 to 3, high urokinase-type plasminogen activator/plasminogen activator inhibitor-1, hormone receptor (HR) negativity, and less than 35 years of age. After an early amendment, all HR-positive tumors underwent recurrence score (RS) testing, with chemotherapy omission recommended in RS less than or equal to 11 pN0 to pN1 disease. Patients were randomly assigned to four cycles of epirubicin (E)90/cyclophoshamide (C)600 followed by four cycles of docetaxel (T)100 or six cycles of T75C600 (administered once every 3 weeks). The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The protocol specified P = .05 for a noninferiority margin of 4.4% for all patients combined. Of the 3,198 registered patients, 348 (RS ≤ 11) omitted chemotherapy, and 401 were not randomly assigned. ...Continue Reading

References

Feb 1, 1987·American Journal of Epidemiology·S D WalterC K Wells
Apr 12, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry D BearNorman Wolmark
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen E JonesLina Asmar
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JonesMichael A Savin
Jun 4, 2010·The New England Journal of Medicine·Sandra M SwainNorman Wolmark
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Jun 16, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Amir SonnenblickJohn Crown
Jun 17, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joseph A SparanoNancy E Davidson
Apr 12, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joanne L BlumNorman Wolmark
Jul 1, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bent EjlertsenHenning T Mouridsen
Jun 5, 2018·The New England Journal of Medicine·Joseph A SparanoGeorge W Sledge

❮ Previous
Next ❯

Citations

Aug 30, 2019·Current Opinion in Oncology·Stefania Morganti, Giuseppe Curigliano
Sep 25, 2019·Nature Reviews. Disease Primers·Nadia HarbeckFatima Cardoso
Feb 23, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzette DelalogeUNKNOWN MINDACT investigators and the TRANSBIG Consortium
Dec 7, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip D PoorvuAnn H Partridge
Aug 12, 2020·Cancer·Matthias ChristgenUNKNOWN West German Study Group PlanB Investigators
Oct 8, 2020·Cancer Medicine·Aditya K SenguptaManjiri M Bakre
Jun 18, 2020·Seminars in Oncology·Elaine M WalshVered Stearns
Apr 5, 2021·Lancet·Sibylle LoiblGiuseppe Curigliano
May 19, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sara M TolaneyLarissa A Korde
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J BursteinUNKNOWN Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019
Aug 6, 2021·JNCI Cancer Spectrum·Arielle S GillmanRebecca A Ferrer
Oct 10, 2021·NPJ Breast Cancer·Sara Alsterlind HurvitzDennis J Slamon
Sep 29, 2020·Breast Care·Julian PuppeWolfram Malter
Feb 1, 2022·Future Oncology·Sara Lopez-TarruellaMiguel Martin
Feb 3, 2022·Breast Cancer Research and Treatment·Jacqueline B VoLene Veiga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

© 2022 Meta ULC. All rights reserved